TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05585307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-6212
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Substudy 03)
Description: Antiretroviral therapy, administered orally
Study: NCT05244590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation model for patients with palliative care needs
Description: Training in PC for GPs The training program for GPs will meet the main training needs of GPs according to our previous study and feedback from elements of the Palliative Care Study Group of the Portuguese Association of General and Family Medicine (GESPal). The training program will have a total duration of 24 hours and will consist of two modules.~Consultation model for patients Consultations will take place every 3 weeks for a total period of 12 weeks. The consultation model will be divided into five areas (Summarize clinical information, Objective symptoms' management, Assessment and coding of chronic diseases and symptoms, planning clinical approach, (other) problems/concerns) to be addressed during the assessment. The five areas were constructed to be intuitive for GPs, following the records' structure used in Portuguese primary care.
Study: NCT05932433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
Study: NCT05969080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment for Self-Injurious Behaviors
Description: Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
Study: NCT05508425

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose tolerance test using water at room temperature
Description: The use of water at room temperature to solve the 75g glucose.
Study: NCT05392075

Intervention type: BIOLOGICAL
Intervention: Pfizer COVID-19 mRNA vaccine
Description: vaccinated people who received the Pfizer COVID-19 mRNA vaccine

Intervention type: BIOLOGICAL
Intervention: Moderna COVID-19 mRNA vaccine
Description: vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine
Study: NCT05028608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Elinzanetant given orally as a single dose in Period 1 and in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: Elinzanetant given orally as a single dose in Period 1 and in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam given orally as single dose in Period 1 and in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam given orally as single dose in Period 1 and in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine given orally twice daily in Period 2 .
Study: NCT05508425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test using hot water
Description: The use of hot water to solve the 75g glucose.
Study: NCT06015984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traning
Description: In order to participate in the training module, a user name and password will be given to the initiative group, the link to be used in the self-managed and asynchronous training platform will be shared, and it will be ensured that it participates in the web-based nurse training, and the training will last for eight weeks.
Study: NCT06532877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Patients and caregivers in the acceptance and commitment therapy arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Support
Description: Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
Study: NCT05635448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching Program
Description: thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
Study: NCT06398639

Intervention type: OTHER
Group type: OTHER
Intervention: Polygenic Risk Score (PRS)
Description: Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.

Intervention type: OTHER
Group type: OTHER
Intervention: Polygenic Risk Score (PRS)
Description: Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.

Intervention type: OTHER
Group type: OTHER
Intervention: Polygenic Risk Score (PRS)
Description: Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.
Study: NCT06177353

Intervention type: OTHER
Intervention: Sampling
Description: Blood sampling Skin biopsy Collection of soiled bandages

Intervention type: OTHER
Intervention: Sampling
Description: Blood sampling Skin biopsy Collection of soiled bandages
Study: NCT05508425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test using cold water
Description: The use of cold water to solve the 75g glucose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test using hot water with tea bag
Description: The use of hot water with tea bag to solve the 75g glucose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test using room temperature water with tea bag
Description: The use of room temperature water with tea bag to solve the 75g glucose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test using cold water with tea bag
Description: The use of cold water with tea bag to solve the 75g glucose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test using bubble water at room temperature
Description: The use of bubble water at room temperature to solve the 75g glucose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test using bubble water
Description: The use of cold bubble water to solve the 75g glucose.
Study: NCT05635448

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No intervention - waitlist control
Description: No intervention - waitlist control
Study: NCT05172947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: This group received resveratrol with the conventional therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group received placebo with the conventional therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Resveratrol plus Pharmaceutical care
Description: This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo+Pharmaceutical care
Description: This group received placebo with Pharmaceutical care in addition to the conventional therapy
Study: NCT05004740

Intervention type: OTHER
Intervention: Vaccinated Pregnant or Lactating persons
Description: vaccinated lactating persons from Sinai Health System or the general public
Study: NCT06524947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris)
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris)
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate
Study: NCT05060042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration group
Description: WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral proprioceptive training
Description: Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week
Study: NCT05428371

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiomic analyses of blood and surgical specimens
Description: The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)

Intervention type: DIAGNOSTIC_TEST
Intervention: Multiomic analyses of blood and surgical specimens
Description: The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)
Study: NCT06584279

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy of the prostate and pathological diagnosis
Description: Whether the index-lesion-contralateral systematic biopsy was performed
Study: NCT04945382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scotchbond Universal 3M
Description: The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
Study: NCT06524947

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate
Study: NCT04945382

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Bond 3M
Description: The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
Study: NCT00850512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP21-R
Description: Four months for CHOP21-R and two treatment days one week apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: 12-week safety period for Zevalin
Study: NCT05629962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
Study: NCT04705480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 50mg
Description: Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neither Pregabalin nor Gabapentin
Description: Patients will receive neither Pregabalin nor Gabapentin.
Study: NCT04894383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aetrex L420 Compete Orthotic
Description: An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aetrex L420 Compete Orthotic
Description: An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aetrex indoor comfort sandal with built-in arch support
Description: An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
Study: NCT04873583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)
Study: NCT06565624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cotton Swab Nasal Stimulation
Description: Nostril probing for the purpose of producing reflex tearing
Study: NCT06088199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablet
Study: NCT05841004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational device
Description: Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
Study: NCT05444244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relational Research Recruitment and Engagement Intervention
Description: * Specified recruiter/point of contact~* Flexibility in study time, place, method of recruitment (preferred participant email, phone), and follow-up (in registry, if participant calls back at all restart 3 failed phone contacts)~* Resource matching (financial, transportation constraints)
Study: NCT01011686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-SM
Description: autologous adipose-derived stem cell
Study: NCT05478915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: discectomy of the TMJ disc
Description: removal of the TMJ disc

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ discopexy
Description: fixation of the TMJ disc
Study: NCT05614947

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Powdered tart cherry
Description: 500 mg freeze-dried tart cherry per capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg colored cornstarch per capsule
Study: NCT05880914

Intervention type: PROCEDURE
Intervention: miRNAseq analysis
Description: Identify miRNA in serum and prepare a miRNA sequencing library for novel analysis.

Intervention type: DRUG
Intervention: Standard treatment for bone disorder
Description: Participants will be prescribed a clinically indicated bone-targeted treatment for osteoporosis or bone disorder related to CKD. (non-experimental)
Study: NCT05032508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaïne Aguettant 20 mg/ml
Description: Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
Study: NCT04874740

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05841004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device
Description: Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator device
Description: Hollister Infyna Chic, single-use compact catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator device
Description: Hollister Infyna Chic, single-use compact catheter.
Study: NCT06392230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral [14C] PF-06821497
Description: A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-06821497
Description: A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV [14C] PF-06821497
Description: A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
Study: NCT06369961

Intervention type: DRUG
Intervention: transdermal fentanyl
Description: Adult cancer pain patients switched from oral opioid to TDF
Study: NCT05924477

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sulcus tube placement
Description: GDD implantation surgery with tube placement in the ciliary sulcus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior chamber (AC) tube placement
Description: GDD implantation surgery with tube placement in the anterior chamber
Study: NCT04918693

Intervention type: DEVICE
Intervention: Ultrasound scanning
Description: All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.

Intervention type: DEVICE
Intervention: Ultrasound scanning
Description: All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
Study: NCT06143384

Intervention type: DEVICE
Intervention: Telemonitoring AirView (ResMed company)
Description: Introduction of AirView telemonitoring of HMV, during a 6-months period.
Study: NCT05612997

Intervention type: OTHER
Intervention: Dietary Assessment
Description: Food Frequency Questionnaire and 24h Recalls.
Study: NCT06508632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandala group
Description: Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).